Tenable Holdings, Inc. : Wedbush Assumes Coverage With Underperform Vs Outperform Rating; Price Target $29
TENB•Related News
Relmada CFO Maged Shenouda acquires $843,140 of common shares
RLMD•
Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser
BLCO•
U.S. FDA extends review of Exelixis' cancer drug
EXEL•
Varonis Systems, Inc. <VRNS.O>: Wedbush assumes coverage with neutral vs outperform rating; price target $46
VRNS•
Lazard Reports August 2026 Assets Under Management
LAZ•